What exactly did Brookline Capital do on March 03, 2026?

Brookline Capital maintained a **Buy** rating on Intellia Therapeutics, Inc. (NTLA) on March 03, 2026 and kept a **$106** price target, per a note published at 09:54 AM and reported on StreetInsider.

How did the market react to the maintained rating?

Shares moved **-3.85% ($-0.54)** on the day of the note, reflecting profit taking and headline sensitivity rather than disagreement with Brookline’s longer-term view.

What does the maintained Buy mean for investors?

A maintained Buy is an analyst’s continued positive view, not a fresh endorsement; investors should weigh the Buy against clinical timelines, cash runway, and personal risk tolerance.

How does Meyka AI view NTLA right now?

Meyka AI rates NTLA with a grade of **B**, reflecting benchmark, sector, growth, metrics, and analyst consensus; this is informational and not financial advice.

Analyst Ratings

Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026

ByDanny Kontos March 4, 2026March 4, 2026

The NTLA analyst rating was maintained at Buy by Brookline Capital on March 03, 2026, and the firm reaffirmed a $106 price target. Brookline’s note was published at 09:54 AM and tracked by StreetInsider. The move was a reiteration rather than an upgrade or downgrade, and the stock showed a short-term reaction of -3.85% ($-0.54). Meyka AI flags this as a confirmation of Brookline’s confidence in Intellia’s pipeline and commercial prospects while noting headline-driven volatility may persist. See Brookline’s release on StreetInsider and our profile at Meyka NTLA profile.